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Abstract: Over the past decade, gradual progress has been made in
improving the outcomes of patients with lung cancer. This review
summarizes the findings from selected studies presented at the
recently concluded 45th annual meeting of the American Society of
Clinical Oncology. This report will focus only on findings that are of
immediate relevance to clinical practice. The topics discussed here
range from the long-term safety of adjuvant chemotherapy and a
new systemic chemotherapy regimen for locally advanced non-small
cell lung cancer to the emerging issue of maintenance chemotherapy
and the use of biomarkers in the treatment of patients with metastatic
non-small cell lung cancer.
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Lung cancer is a leading cause of cancer-related mortalityglobally. Over the past decade, a few notable advances
have been made in the treatment of non-small cell lung cancer
(NSCLC). Adjuvant chemotherapy improves survival in pa-
tients with resected stages II and III NSCLC. Inhibitors of
epidermal growth factor receptor tyrosine kinase (EGFR TK)
such as gefitinib and erlotinib produce striking responses in
patients with activating mutations in the EGFR TK domain.
Systemic chemotherapy continues to play an important role in
the treatment of advanced NSCLC, however. This brief
review summarizes the key presentations from the recently
concluded 45th annual meeting of the American Society of
Clinical Oncology (ASCO). Continued work in these areas
presented at this meeting has improved our understanding of
the role of EGFR TK inhibitors in the front line therapy for
advanced NSCLC, provided reassuring data on the safety of
adjuvant chemotherapy and have made us rethink about the
current paradigm of administering chemotherapy only for a
limited duration in the front line setting for patients with
metastatic disease.
RESECTABLE NSCLC
Administration of cisplatin-based chemotherapy im-
proves overall survival (OS) in patients with resected stages
II and III NSCLC.1–3 Nevertheless, several questions remain
with regard to use of adjuvant chemotherapy in this setting.
How best to identify patients who are not likely to relapse, so
that they can be spared of the toxicities of adjuvant therapy?
Are there any molecular markers of predictors of response to
platinum based therapy? Could there be any long-term con-
sequences, especially given the fact that we have begun using
adjuvant chemotherapy in NSCLC only recently? Finally, is
there still a role for neoadjuvant chemotherapy and how does
it fare against adjuvant chemotherapy. Some of these ques-
tions were addressed at this meeting.
At the annual meeting of ASCO last year, the investi-
gators from International Adjuvant Lung Trial (IALT) pre-
sented a diminishing benefit from adjuvant chemotherapy
over time [from a hazard ratio (HR) of 0.86 (p  0.03) at 4.7
years to a HR of 0.91 (p  0.10) at 7.5 years].4 There was an
unexpected increase in the mortality from nonlung cancer
deaths in patients treated with chemotherapy in the IALT
study. Naturally, these disturbing findings prompted the Ca-
nadian investigators to analyze the long-term follow-up data
from the adjuvant study, JBR.10. This randomized phase III
trial compared vinorelbine and cisplatin with observation in
completely resected stages IB and II NSCLC. A total of 482
patients were randomized to chemotherapy or observation,
and arms were well balanced for clinical and pathologic
characteristics. At the time of the initial report in April 2004,
there was an overall benefit with chemotherapy in the intent
to treat population (HR  0.69, p  0.009) at a median
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follow-up time of 5.2 years. The survival benefit was seen
only in patients with stage II disease (HR  0.59, p 
0.004).2 In the updated analysis at this meeting, now with a
median follow-up time of 9.3 years, the survival advantage
with chemotherapy remained clinically and statistically sig-
nificant for the entire population (HR 0.78, p  0.04) and
more so in patients with stage II disease (HR  0.68, p 
0.01).5 Most importantly, unlike the IALT, there was no
increase in nonlung cancer mortality in patients treated with
adjuvant chemotherapy. Table 1 summarizes the available
data with regard to the efficacy of adjuvant chemotherapy
including changes in survival benefit over time. Although
there are no clear explanations for the increased nonlung
cancer deaths in patients treated with adjuvant therapy in the
IALT study, the data from the JBR.10 are quite reassuring.
The available data thus support a continued long-term sur-
vival benefit from adjuvant cisplatin based therapy at least as
of now.
The role of preoperative chemotherapy in patients with
resectable NSCLC has not been well defined. A meta-analy-
sis of seven randomized controlled clinical trials of neoadju-
vant chemotherapy versus surgery alone showed an improved
survival with chemotherapy with a HR of 0.82 [95% confi-
dence interval (CI); 0.69–0.97] somewhat comparable with
the efficacy of chemotherapy reported in the adjuvant set-
ting.6 The Chemotherapy for Early Stages Trial study pre-
sented at ASCO 2008 showed a benefit from three cycles of
neoadjuvant gemcitabine with cisplatin (HR 0.63, 95% CI;
0.42–0.93).7 At ASCO this year, the NATCH trial was
presented, which randomized 624 patients with stages IA–
IIIA clinically staged disease to surgery alone or three cycles
of neoadjuvant or adjuvant carboplatin with paclitaxel.8 The
primary end point was disease-free survival (DFS). Half the
patients enrolled in this study had pathologically confirmed
stage I NSCLC. Chemotherapy delivery was superior in the
neoadjuvant arm with 97% receiving treatment, when com-
pared with only 66% in the adjuvant arm. There were no
differences in DFS between the adjuvant and surgery alone
arms, although there was a trend toward improvement in DFS
in patients treated with neoadjuvant therapy (HR 0.92, p
0.176). This trend was stronger in patients with stage II or III
disease (HR  0.81, p  0.07). Preliminary OS data showed
no differences between the arms. The study results are diffi-
cult to interpret because of the large proportion of patients
with stage I disease who are not known to benefit from
systemic chemotherapy. These results, in our opinion, do not
change the current practice of offering cisplatin based adju-
vant therapy in patients with resected stages II and III
NSCLC.
Because of the relatively modest benefit with adjuvant
chemotherapy, identification of patients likely to respond to
adjuvant chemotherapy would be of great benefit. A molec-
ular analysis of a subset of patients enrolled in the IALT
suggested that only those patients whose tumors had low
expression of ERCC1 (a deoxyribonucleic acid repair en-
zyme) had a benefit with adjuvant treatment.9 In the JBR.10
trial, patients whose tumors had K-ras mutations did not
benefit from adjuvant chemotherapy.2 This year, a second
subset analysis of the IALT was presented evaluating the
expression of another deoxyribonucleic acid repair protein,
MutS homolog 2 (MSH2).10 Of 1867 patients enrolled in the
IALT study, 673 had evaluable tumors, of which 257 (38%)
were considered MSH2 positive and 416 (62%) were MSH2
negative. There was a long-term survival benefit with che-
motherapy in the MSH2 negative group (HR  0.76, p 
0.03) but not in the MSH2 positive group (HR  1.12, p 
0.48). MSH2 expression also had prognostic utility in patients
assigned to observation only in which MSH2 expression was
associated with a survival benefit (HR 0.66, p 0.01). The
combined expression data for ERCC1 and MSH2 were avail-
able in 658 patients. The survival benefit associated with each
marker was independent. It is conceivable that we will soon
be able to select patients likely to respond to cytotoxic
chemotherapy. Prospective validation of the markers such as
ERCC1, MSH2, or K-Ras in the adjuvant setting is necessary
before being considered for use in routine clinical practice.
LOCALLY ADVANCED NSCLC
The treatment of locally advanced NSCLC is evolving
with regard to type and schedule of chemotherapy, integra-
tion of molecularly targeted agents, dose and schedule of
radiation, and the role of surgery. The CALGB 30407 is a
randomized phase II trial of carboplatin (area under the curve
5)and pemetrexed (500 mg/m2) administered every 3 weeks
for four cycles with or without cetuximab (400 mg/m2 load-
ing and 250 mg/m2 weekly for 7 weeks) given concurrently
with radiotherapy (70 Gy over 7 weeks) for patients with
locally advanced NSCLC.11 Pemetrexed was continued for
four cycles after completion of the radiotherapy. All patients
TABLE 1. Overall Survival Benefit in Adjuvant Chemotherapy Trials by Stage and Duration of Follow-Up
IALT4 CALGB40 JBR.105 ANITA3
Follow-up (yr) 4.7 7.5 4 6.2 5.2 9.3 6.3
Overall survival benefit
by stage
IB HR 0.62 (p  0.03) 0.83 (p  0.12) 0.94 (p  0.79) 1.03 (p  0.87) 1.14 (p  NS)
II HR *0.86 (p  0.03) *0.91 (p  0.10) 0.59 (p  0.01) 0.68 (p  0.01) 0.67 (p  0.05)
IIIA HR 0.60 (p  0.05)
Stage distribution by study: IALT: IA (10%), IB (27%), II (25%), and III (39%); CALGB: IB (100%); JBR.10: IB (45%), II (55%); and ANITA: IB (36%), II (24%), III (39%).
*Stage-specific outcomes not reported in IALT. Pooled results for all stages shown here.
IALT, International Adjuvant Lung Trial; CALGB, Cancer and Leukemia Group B, HR, hazard ratio.
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had mandatory pretreatment Fludeoxyglucose-8 positron
emission tomography. The primary end point was OS. It was
determined that if either arm achieved a median OS of 20.9
months or greater, further exploration would be appropriate.
The overall median survival for both arms of the trial was 22
months with a trend for better survival in the patients with
nonsquamous histology (22 versus 18 months). Incidences of
hematologic toxicity, esophagitis, and pneumonitis were con-
sistent with expected toxicities for concurrent chemoradiation
and were not significantly increased with the addition of
cetuximab. Tissue was collected for biomarkers, but the
results were not reported. It is reasonable to conclude that
pemetrexed and carboplatin can be delivered safely in full
systemic doses concurrent with radiotherapy with or without
cetuximab. The median survival of 22 months is quite prom-
ising, though large phase III definitive studies should be done
before considering this approach as a standard of care. The
PROCLAIM trial is one such large global phase III study that
will compare cisplatin and pemetrexed with cisplatin and
etoposide given concurrently with thoracic radiotherapy in
stage III unresectable disease. The role of cetuximab in the
treatment of locally advanced NSCLC is being tested in the
ongoing intergroup study led by the Radiation Therapy On-
cology Group.
METASTATIC NSCLC
First-Line Therapy
The addition of bevacizumab, a monoclonal antibody
against vascular endothelial growth factor (VEGF), and the
addition of cetuximab, a monoclonal antibody against the
EGFR, to standard platinum-based therapy has demonstrated
a statistically significant improvement in progression-free
survival (PFS) and/or OS in comparison with platinum-based
therapy alone.12–15 The safety of adding both cetuximab and
bevacizumab to a platinum-based doublet therapy was inves-
tigated in a single arm phase II trial performed by the
Southwest Oncology Group (SWOG).16 The primary end
point was defined by the frequency of grade 4 hemorrhagic
toxicities, and secondary end points included response rate
(RR), PFS, and OS. Patients with previously untreated
nonsquamous NSCLC received carboplatin area under the
curve of 6, paclitaxel (200 mg/m2), cetuximab (400 mg/m2
week 1 and 250 mg/m2 weekly), and bevacizumab (15 mg/
kg) every 3 weeks for up to six cycles, and then received
cetuximab weekly and bevacizumab every 3 weeks until
disease progression or unacceptable toxicity. Of the 110
patients enrolled, 104 were assessable. The trial met the
primary end point with a rate of grade 4 hemorrhage of 2%
(95% CI, 0–7%), and there were four treatment-related
deaths [pulmonary hemorrhage (n  2), infection (n  1),
and unknown (n  1)]. With a median follow-up of 15
months, the PFS was 7 months (95% CI, 6–8), and OS was
14 months (95% CI, 11–20). The RR (n  95) observed was
54% (95% CI, 43–64%). An exploratory analysis of biomar-
kers revealed that K-ras (n  32) and EGFR mutation (n 
33) were not predictive of benefit. This combination should
be considered investigational at the present time. A large
phase III study is being conducted by SWOG to assess the
efficacy of this novel regimen.
Maintenance Therapy (“Early Second Line
Therapy”)
Several trials presented at this meeting investigated the
treatment paradigm of initiating an approved second-line
agent immediately after completion of a defined number of
cycles of first-line platinum-based therapy before disease
progression.17–19 Three studies individually explored the role
of pemetrexed, erlotinib in patients treated with platinum-
based doublet therapy and addition of erlotinib to bevaci-
zumab in patients initially treated with a regimen containing
bevacizumab.
The preliminary results of a phase III trial of pem-
etrexed plus best supportive care versus placebo plus best
supportive care were presented last year,20 and the final
results were presented this year.17 Patients were initially
treated with four cycles of platinum-based therapy, and those
without evidence of disease progression and a performance
status (PS) of 0 or 1 were randomized to pemetrexed (500
mg/m2) (n  441) or placebo (n  222) every 3 weeks until
they have disease progression or unacceptable toxicities. The
primary end point was PFS, and OS was a secondary end
point. The final results in the overall study population re-
vealed an improvement in PFS and OS with immediate
pemetrexed in comparison with placebo (Table 2). Based on
a previously observed interaction between pemetrexed and
nonsquamous histology,21,22 a subset analysis was performed
for patients with nonsquamous (n  482) and squamous
histology (n  181). Patients whose tumors had nonsqua-
mous histology experienced a significantly superior PFS
(HR  0.47, 95% CI, 0.37–0.6, p  0.00001; median PFS of
4.4 and 1.8 months, respectively) and OS (HR  0.70, 95%
CI, 0.56–0.88, p  0.002; median OS of 15.5 and 10.3
months, respectively). In contrast, patients with squamous-
type NSCLC did not experience an improvement in PFS
(HR 1.03, 95% CI, 0.77–1.5, p 0.896, median PFS of 2.4
and 2.5 months, respectively) or OS (HR  1.07, 95% CI,
0.49–0.73, p  0.678, median OS of 9.9 and 10.8 months,
respectively). The treatment-related grade 3/4 toxicities ob-
served at statistically significant higher rate on the pem-
etrexed treatment arm were fatigue (5% versus 0.5%) and
neutropenia (2.9% versus 0%). Nearly two thirds of patients
assigned to placebo received subsequent therapy on disease
progression (67%). Preliminary quality of life (QoL) data
using the Lung Cancer Symptom Scale to estimate the time to
worsening of symptoms was presented at the ASCO 2008
meeting, and HR for time to worsening of symptoms showed
no significant difference but favored the pemetrexed treat-
ment arm.23 Based on the improvement in OS in this study,
pemetrexed was approved on July 2, 2009, by the U.S. Food
and Drug Administration for maintenance treatment of pa-
tients with locally advanced or metastatic nonsquamous
NSCLC whose disease has not progressed after four cycles of
platinum-based first-line chemotherapy.24
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The trial by Cappuzzo et al.19 investigated the impact of
erlotinib in comparison with placebo in patients who had not
experienced disease progression after four cycles of first-line
platinum-based therapy. Patients were enrolled at the time of
initiating chemotherapy (n  1949), and 889 patients were
randomized to erlotinib 150 mg daily (n  438) or placebo
(n  451) until disease progression or unacceptable toxicity.
The primary end point was PFS, and coprimary end point was
PFS in patients whose tumors demonstrate increased EGFR
expression using IHC. Patients were assessed for disease
progression every 6 weeks from time of randomization. The
PFS was significantly prolonged among patients who re-
ceived erlotinib in comparison with patients who received
placebo according to investigator assessment and confirmed
by independent radiologic review (HR  0.71, 95% CI,
0.62–0.82; p  0.0001; median PFS of 12.3 and 11.1 weeks)
and among patients with EGFR expression by IHC (HR 
0.69, 95% CI, 0.58–0.82; p  0.0001). Patients with both
adenocarcinoma and squamous carcinoma histology and
whose tumors were EGFR wild type and with activating
EGFR mutations experienced a significantly longer PFS in
comparison with placebo. The rate of all grades adverse
events were higher on the erlotinib arm in comparison with
placebo including rash (60% versus 9%), and diarrhea
(20% versus 2%), and the rate of grade 3/4 rash and
diarrhea on the erlotinib arm was 9% and 2%, respectively.
No deterioration of QoL as assessed by the Functional
Assessment of Cancer Therapy-Lung was observed on the
erlotinib or placebo arms.
The trial by Miller et al.18 investigated the impact of the
addition of erlotinib to bevacizumab in comparison with
bevacizumab alone after initial treatment with platinum-
based therapy in combination with bevacizumab. Patient with
treated brain metastases were eligible, and patients were
initially were required to have nonsquamous histology, but
after the trial was initiated, it was amended to include patients
with extrathoracic and peripheral squamous cell cancers. The
primary end point was PFS, and this trial was closed after the
data monitoring committee determined that the trial had met
the primary end point after a planned interim efficacy anal-
ysis. The median follow-up is 8.3 months from randomization
(range, 0–24.4 months). Patients who received bevacizumab
and erlotinib experienced a superior PFS in comparison with
patients who received bevacizumab alone (HR  0.722, 95%
CI, 0.592–0.881; p  0.0012; median PFS 3.75 and 4.76
months, respectively) according to investigator assessment.
The subset of patients with squamous histology (n  17) is
too small to make any assessment of the efficacy and safety
of bevacizumab alone or in combination with erlotinib. The
rate of grade 3/4 adverse events was higher of the bevaci-
zumab and erlotinib arm in comparison with bevacizumab
alone (44.1% versus 30.4%); the rate of grade 3/4 rash
(10.4% versus 0.5%) and diarrhea (9.3% versus 0.8%) were
higher on the erlotinib containing treatment arm. The per-
centage of patients who received subsequent therapy was
similar among patients on the bevacizumab and placebo arm
and bevacizumab and erlotinib arms, 55.5% and 50.3%,
respectively. Approximately 40% of patients received erlo-
tinib as subsequent therapy on both arms. Independent radio-
logic review is being conducted, and OS is expected to be
available later in 2009.
In summary, these trials demonstrate that the earlier
initiation of a second-line agent can improve the PFS, which
was the primary end point for all three trials, and more
patients will receive second-line therapy when initiated early.
The trial by Belani et al. demonstrated an improvement in OS
in the overall study population, but consistent with previous
other studies, the benefit of pemetrexed was limited to the
nonsquamous patient population. The OS is not available for
the trials reported by Drs. Miller and Cappuzzo. The QoL
assessment was equivalent on the two treatment arms in the
trial reported by Dr. Cappuzzo, and updated QoL data is
currently not available for the trial reported by Dr. Belani.
The strategy of initiating second-line therapy before disease
progression should be considered as a treatment option, but
the decision to use these treatment strategies should be made
on an individual patient basis depending on variety of clinical
factors (i.e., PS, histology, tolerance of first-line therapy, and
severity of disease-related symptoms) and patient’s prefer-
TABLE 2. Trials of Maintenance Therapy in Advanced NSCLC Presented at ASCO 2009
First Author Comparison (n)
Hazard Ratio
PFS (95% CI) OS (95% CI)
Belani et al. Pemetrexed (441) and placebo (222) 0.60 (0.49–0.73), p  0.00001 0.79 (0.65–0.95), p  0.012
Subset Nonsquamous (481) 0.47 (0.37–0.6), p  0.00001 0.70 (0.56–0.88), p  0.002
Squamous (182) 1.03 (0.77–1.5), p  0.896 1.07 (0.49–0.73), p  0.678
Cappuzzo et al. Erlotinib (438) and placebo (451) 0.71 (0.62–0.82), p  0.0001 Not available
Subsets Adenocarcinoma (401) 0.60 (0.48–0.75, p  0.0001 Not available
Squamous (359) 0.76 (0.60–0.95), p  0.0148 Not available
EGFR, wild type (388) 0.78 (0.63 to 0.96), p  0.0185 Not available
EGFR, mutation (49) 0.10 (0.04 to 0.25), p  0.0001 Not available
EGFR IHC () (681) 0.69 (0.58 to 0.82), p  0.0001 Not available
Miller et al. Bevacizumab  placebo (373) and bevacizumab 
erlotinib (370)
0.722 (0.592 to 0.881), p  0.0012 Not available
NSCLC, non-small cell lung cancer; CI, confidence interval; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry.
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ences. The cost implications for pursuing this approach (for
all its modest benefits) have not been evaluated.
Second Line
Vandetanib is an oral agent that is a dual inhibitor of the
VEGF and EGFR pathways. A randomized phase II trial in
previously treated patients with NSCLC comparing docetaxel
with vandetanib plus docetaxel showed an improvement in
PFS favoring the combination.25 These results prompted the
ZODIAC trial, which is a double-blind phase III trial that
randomized 1391 patients to receive docetaxel (75 mg/m2
every 3 weeks) plus vandetanib (100 mg daily orally) or
docetaxel and placebo for the second-line treatment of ad-
vanced NSCLC.26 The primary end point was a 25% im-
provement in PFS for vandetanib and docetaxel. The RR and
PFS were both statistically significant in favor of the vandet-
anib study arm. There was no difference in OS between the
two arms. The toxicities were similar between the study arms
except for rash, which was more prevalent among the van-
detanib treated patients. Of note, there was no increase in the
toxicities typically associated with anti-VEGF treatment (i.e.,
hemoptysis and thrombosis). A QoL analysis using the Func-
tional Assessment of Cancer Therapy-Lung assessment tool
indicated prolongation of the time to deterioration of symp-
toms for patients treated with vandetanib and docetaxel (HZ
0.77, p  0.001). Another phase III trial of similar design,
ZEAL, was also reported at this meeting.27 Five hundred
thirty-four patients were randomized to receive pemetrexed
(500 mg/m2 every 3 weeks) and vandetanib (100 mg daily
orally) or placebo. The survival outcomes were very similar
to those in the ZODIAC trial but were not statistically
significant probably secondary to the smaller patient sample
size on the ZEAL trial (Table 3). Biomarkers were done on
tissue samples collected in the ZODIAC trial. Unfortunately,
tissue was available on only 25% of the study population, and
numbers were too small to make any definitive conclusions
regarding the potential ability of these markers to predict
benefit from treatment. Considering that both these trials
show a very modest benefit in an unselected group of pa-
tients, it would be difficult to recommend routine use of
vandetanib in combination with docetaxel or pemetrexed
based on these data. It is of utmost importance to establish
reliable, predictive biomarkers that will refine treatment se-
lection for patients, so that the maximum therapeutic benefit
with this agent can be realized. At the present time, vandet-
anib is not available commercially.
SMALL CELL LUNG CANCER
Little progress has been made in chemotherapy for
small cell lung cancer (SCLC) over the past 20 years. Based
on superior outcomes in the JCOG 9511 trial, irinotecan and
cisplatin (IC) is now the standard of care in Japan.28 Never-
theless, SWOG 0124, a study that compared the same regi-
men (PE versus IC) in the U.S. population found no differ-
ences in outcomes.29 To explain these contrasting outcomes,
the SWOG and the Japanese investigators directly compared
the two studies at ASCO this year. The JCOG study con-
tained fewer women (14% versus 43%) and fewer PS 0
patients (12% versus 32%) than the SWOG study. The JCOG
study had more severe neutropenia and anemia in each arm
compared with the SWOG study (p  0.001). Response rates
were also higher for each arm in Japanese when compared
with U.S. patients (p  0.01). OS was similar in the PE arms
for both population but Japanese patients had significant
improvements with IC, when compared with U.S. patients
(12.8 versus 9.9 months; p 0.001).30 These findings suggest
the possibility of significant inherited differences in the me-
tabolism of irinotecan accounting for differing outcomes
between the Japanese and SWOG study with irinotecan. A
randomized study comparing carboplatin-etoposide with car-
boplatin-irinotecan in European patients with extensive stage
SCLC presented at this meeting showed no differences in
outcomes, though more hematologic toxicities with etoposide
and more nonhematologic toxicities with irinotecan.31
For second-line treatment of SCLC, topotecan is ap-
proved in the United States, and amrubicin is standard of care
in Japan. A randomized phase II study of these two agents in
the U.S. population was presented, which showed significant
improvements in RR with amrubicin (44% versus 11.5%, p
0.005) compared with topotecan.32 The PFS and OS were
slightly improved with amrubicin, 9.3 versus 7.7 months and
4.6 versus 3.3 months, respectively, but these were not
statistically significant. Amrubicin may have a role for sec-
ond-line treatment of SCLC in Western population and is
currently being evaluated in a phase III study.
MALIGNANT PLEURAL MESOTHELIOMA
Malignant pleural mesothelioma (MPM) remains
largely an incurable disease. The role of resection for patients
with localized disease remains controversial. A SEER study
of the incidence and outcomes of surgically treated MPM
presented at this meeting reported that of the 3300 new cases
TABLE 3. Results of ZODIAC and ZEAL Trials
TRIAL
Treatment
ZODIAC ZEAL
Docetaxel  Vandetanib (694) Docetaxel  Placebo (697) Pemetrexed  Vandetanib (256) Pemetrexed  Placebo (278)
RR (%) 17a 10 19a 8
DC at 6 wk (%) 60 55 57a 46
PFS (mo) 4.0 (HR 0.79)a 3.2 4.0 (HR 0.86) 2.8
OS median (mo) 10.6 (HR 0.91) 10.0 10.5 (HR 0.86) 9.2
OS at 1-yr (%) 44.7 41.2 NR NR
a p  0.05.
RR, response rate; DC, disease control; PFS, progression free survival; OS, overall survival; HR, hazard ratio; ZODIAC and ZEAL trials; Refs 25 and 26.
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each year in the United States only 11% of patients receive
any type of definitive surgical resection.33 The median OS of
patients treated with surgery was only 13 months, with 5-year
survival of 12%, when compared with 3% in patients treated
nonoperatively. Surgery seems to only marginally improve
the outcomes in patients with malignant mesothelioma. A
second study was presented, which evaluated the feasibility
of induction cisplatin-pemetrexed, given the efficacy of this
regimen in the metastatic setting. Patients were treated with
chemotherapy, extrapleural pneumonectomy, and postopera-
tive radiotherapy. Of the 49 patients enrolled, seven (14%)
had treatment-related mortality with an OS of 18.4 months.34
The benefit associated with neoadjuvant therapy seems to be
modest at best in mesothelioma.35,36
Tumors with elevated thymidylate synthase (TS) have
been shown to be relatively resistant to pemetrexed in other
malignancies. A study of TS levels in 50 patients with
epithelial MPM was presented and showed that low-TS
protein expression was associated with a longer progression
free and OS (40 versus 16 months, p  0.01) when treated
with pemetrexed, but these findings need to be validated in
large prospective studies.37
PREDICTIVE VALUE OF BIOMARKERS
The biomarker data from the recently reported iPASS
trial were particularly instructive.38 The iPASS study is a
phase III randomized trial, conducted in Asia, which com-
pared gefitinib with carboplatin and paclitaxel in patients with
advanced NSCLC of the adenocarcinoma subtype who are
never smokers or light smokers. The presence of an activating
mutation in the EGFR TK inhibitor domain was the best
predictor of response with 71.2% of mutation positive pa-
tients responding to gefitinib in comparison with 58.8% of the
EGFR-FISH-positive patients and 51.5% of IHC-positive
patients. In sharp contrast, only 1.1% of mutation negative
patients responded to gefitinib. Mutation-positive patients
treated with gefitinib also had improved PFS compared with
mutation positive patients treated with chemotherapy (9.5
versus 6.3 months: HR  0.48; p  0.0001), whereas the
reverse was true for mutation negative patients (1.5 versus 5.5
months; HR  2.85; p  0.0001). The PFS was also sub-
stantially better with gefitinib in mutation positive versus
mutation negative patients (9.5 versus 1.5 months). There
was also significant overlap among the three markers with
40.1% of patients being positive for all three biomarkers and
60, 62, and 74% of patients being positive for EGFR muta-
tion, FISH and IHC, respectively. Of the patients who were
FISH positive, 83.3% of the patients were also mutation
positive. In FISH-positive patients, the HRs for PFS favored
gefitinib if they were also mutation positive (0.48) and fa-
vored chemotherapy if they were mutation negative (3.85).
This suggests that FISH-positive patients derive benefit from
gefitinib only if they are also mutation positive, and therefore
the mutation status emerges as the best predictor of improved
response and PFS with gefitinib. Even though the OS favored
gefitinib in mutation-positive patients (HR  0.78; 95% CI
0.50–1.20) and favored chemotherapy in the mutation-nega-
tive patients (HR  1.38; 95% CI 0.92–2.09), in both in-
stances the HR crossed unity. This could be explained by the
fact that there was significant cross over in both arms and
with 39% of patients in each arm crossing over and receiving
gefitinib if originally assigned to chemotherapy and vice
versa.
The biomarker data from the FLEX trial were less
definitive.39 This was a phase III randomized trial that added
cetuximab to cisplatin and vinorelbine in patients with ad-
vanced NSCLC who were also EGFR positive by IHC. There
was a statistically significant improvement in OS in the
cetuximab arm (11.3 versus 10.1 months; HR  0.87, p 
0.04). K-ras mutational status and EGFR-FISH status were
the biomarkers examined in this trial. Nineteen percent of the
patients were K-ras positive, whereas 37% of the patients
were EGFR-FISH positive. This contrasts with 62% of pa-
tients being EGFR-FISH positive in the select iPASS popu-
lation of patients. The FISH status did not predict for im-
proved response, PFS, or OS for treatment with cetuximab.
Interestingly and contrary to the colon cancer experience, the
presence of K-ras mutations was not a negative predictor for
clinical benefit for cetuximab. Nevertheless, the number of
patients with K-ras mutations who received cetuximab is
small, and additional studies are needed before definitive
conclusions can be derived. Corroborating previous observa-
tions, rash during the first cycle was a good predictor of
response to cetuximab. For the 56% of the patients in the
cetuximab arm who had any grade rash, the median OS was
15 months versus 10.3 months if there was no rash (HR 
0.631, p  0.001). Therefore, it seems that rash may be the
best predictor of clinical benefit with cetuximab rather than a
molecularly based marker.
The biomarker data from ASCO 2009 strengthen the
rationale for using EGFR TK mutation analyses to select
patients likely to benefit from front line therapy with gefitinib
(and presumably erlotinib). Clinical characteristics (including
smoking status) alone are insufficient to guide therapy in the
frontline setting. Unlike the experience with colon cancer,
K-ras mutation status in lung cancer does not reliably identify
patients likely to benefit from cetuximab.
SUMMARY
The issue of maintenance (or early second line) che-
motherapy in advanced stage NSCLC has become a major
topic for discussion and debate. It seems that the field is
moving toward using EGFR TK mutation to identify patients
who are likely to benefit from frontline gefitinib (or erlotinib)
therapy. Pemetrexed-based chemotherapy regimen in combi-
nation with thoracic radiation seems feasible and is being
studied in a large global phase III study. Finally, we are
poised to use biomarkers to guide adjuvant therapy. Although
there were no major breakthroughs in the treatment of lung
cancer reported at this ASCO meeting, these studies collec-
tively represent small steps of progress in the right direction.
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